LearnGlossaryMarketStocksSuperinvestorsSign in

TECX

Tectonic Therapeutic, Inc.

Healthcare · $439M market cap

Verdict

We can't put a fair value on TECX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-28.1% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-51.3%✗

Follow TECX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 3, 2026: no open-market purchases and 5 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

REICIN ALISE

Chief Executive Officer · 2026-09-03

Award

$2.1M

Ruddy Marcella K.

Chief Medical Officer · 2026-09-03

Award

$726K

Lochner Daniel

Chief Financial Officer · 2026-09-03

Award

$726K

McNamara Peter

Chief Scientific Officer · 2026-09-03

Award

$628K

Schwabish Marc

Chief Business Officer · 2026-09-03

Award

$531K

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works